Trial reportThe British journal of general practice : the journal of the Royal College of General Practitioners2010
Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings.
Trial report in The British journal of general practice : the journal of the Royal College of General Practitioners, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Economic Evaluations of Medication Safety Interventions in Primary and Long-Term Care: A Systematic Review.PharmacoEconomics · 2026Pooled it
- Systematic literature review of pharmacists in general practice in supporting the implementation of shared care agreements in primary care.Systematic reviews · 2022Pooled it
- Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations.PharmacoEconomics · 2022Pooled it
- Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review.PharmacoEconomics · 2019Pooled it
- Community-Level Pharmaceutical Interventions to Reduce the Risks of Polypharmacy in the Elderly: Overview of Systematic Reviews and Economic Evaluations.Frontiers in pharmacology · 2019Pooled it
- Trial
- Trial
- Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings.The British journal of general practice : the journal of the Royal College of General Practitioners · 2010Trial
- Evaluation of pharmaceutical care services in the Middle East Countries: a review of studies of 2013-2020.BMC public health · 2023Review
- A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions.PharmacoEconomics · 2014Review
- Economic evaluation of policy initiatives in the organisation and delivery of healthcare: a case study of gastroenterology endoscopy services.Cost effectiveness and resource allocation : C/E · 2014Article
- Medication assessment tool to detect care issues from routine data: a pilot study in primary care.International journal of clinical pharmacy · 2013Article
- Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?PharmacoEconomics · 2013Article
- Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital.BMJ open · 2013Article
- New models of emergency prehospital care that avoid unnecessary conveyance to emergency department: translation of research evidence into practice?TheScientificWorldJournal · 2013Article
- The role of the pharmacist in optimizing pharmacotherapy in older people.Drugs & aging · 2012Review
- NICE work: how NICE decides what we should pay for.The British journal of general practice : the journal of the Royal College of General Practitioners · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundPharmaceutical care serves as a collaborative model for medication review. Its use is advocated for older patients, although its cost-effectiveness is unknown. Although the accompanying article on clinical effectiveness from the RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the Community over Time) trial finds no statistically significant impact on prescribing for older patients undergoing pharmaceutical care, economic evaluations are based on an estimation, rather than hypothesis testing.
aimTo evaluate the cost-effectiveness of pharmaceutical care for older people compared with usual care, according to National Institute for Health and Clinical Excellence (NICE) reference case standards.
methodsAn economic evaluation was undertaken in which NICE reference case standards were applied to data collected in the RESPECT trial.
resultsOn average, pharmaceutical care is estimated to cost an incremental 10 000 UK pounds per additional quality-adjusted life year (QALY). If the NHS's cost-effectiveness threshold is between 20 000 and 30 000 UK pounds per extra QALY, then the results indicate that pharmaceutical care is cost-effective despite a lack of statistical significance to this effect. However, the statistical uncertainty surrounding the estimates implies that the probability that pharmaceutical care is not cost-effective lies between 0.22 and 0.19. Although results are not sensitive to assumptions about costs, they differ between subgroups: in patients aged >75 years pharmaceutical care appears more cost-effective for those who are younger or on fewer repeat medications.
conclusionAlthough pharmaceutical care is estimated to be cost-effective in the UK, the results are uncertain and further research into its long-term benefits may be worthwhile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.